



(43) International Publication Date
30 July 2015 (30.07.2015)

(10) International Publication Number
WO 2015/112970 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) G01N 33/53 (2006.01)
G01N 33/573 (2006.01)

(21) International Application Number:

PCT/US2015/012885

(22) International Filing Date:

26 January 2015 (26.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/931,878 27 January 2014 (27.01.2014) US
61/990,932 9 May 2014 (09.05.2014) US

(71) Applicant: MEDIMMUNE, LLC [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: STREICHER, Katie; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). YAO, Yihong; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). RANADE, Koustubh; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). LIANG, Meina; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). VAIN-SHTEIN, Inna; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). PIPER, Edward; c/o MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). MAY,

Richard; c/o MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). NORDENMARK, Lars; c/o Astrazeneca, Pepparedsleden 1, S-431 83 Mölndal (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DIPEPTIDYL PEPTIDASE-4 (DPP4/CD26) AS A PERIPHERAL BIOMARKER OF IL-13 ACTIVATION IN ASTHMATIC LUNG

(57) Abstract: The present disclosure relates to the use of DPP4, protein or gene expression levels, as a biomarker for IL-13 mediated diseases or disorders, e.g., asthma, IPF, COPD or atopic dermatitis. Levels of the DPP4 biomarker above or below a predetermined DPP4 threshold level can be used (i) to determine a patient's eligibility for a certain treatment with a IL-13 antagonist, (ii) to determine whether a certain treatment of an IL-13 mediated condition or disorder with a specific IL-13 antagonist should commence, be suspended, or be modified, (iii) to diagnose whether an IL-13 mediated condition or disorder is treatable or not treatable with a specific IL-13 antagonist, (iv) to prognosticate the outcome of treating an IL-13 mediated condition or disorder with a specific IL-13 antagonist. The disclosure further provides assay kits for the detection of DPP4, as well as computer implemented diagnostic methods.



WO 2015/112970 A1